Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VBY-376
- Development stage
- Phase 1
- Lead developer
- Virobay
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VBY-376 is a small molecule drug developed by Virobay for the treatment of hepatitis C and other liver-related diseases. It acts as an inhibitor of cathepsin B (CTSB) and the hepatitis C virus (HCV) nonstructural proteins NS3 and NS4, which are proteases essential for viral replication. The drug was investigated primarily as an antiviral agent targeting HCV infection, with additional development efforts in hepatic fibrosis and non-alcoholic steatohepatitis. Clinical trials included phase 1 studies evaluating safety and pharmacokinetics in healthy adults[1][2][3][4]. Development for hepatitis C has been discontinued, while no further development has been reported for hepatic fibrosis or non-alcoholic steatohepatitis[2].
- Other names
- VBY 376VBY376VBY-376
02
Targets
CTSB (Cathepsin B)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS3 (Dengue virus NS3 protein)CDKN1B (Transmembrane emp24 domain-containing protein 7)
Beyond the preview
Go deeper on VBY-376.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VBY-376.